Bovi-Shield IBR (Canada)This page contains information on Bovi-Shield IBR for veterinary use.
The information provided typically includes the following:
- Bovi-Shield IBR Indications
- Warnings and cautions for Bovi-Shield IBR
- Direction and dosage information for Bovi-Shield IBR
Bovi-Shield IBRThis treatment applies to the following species:
Bovine Rhinotracheitis Vaccine
Modified Live Virus
Bovi-Shield IBR Indications
Bovi-Shield IBR is for vaccination of healthy, nonpregnant cattle to prevent respiratory disease caused by infectious bovine rhinotracheitis (IBR) virus. A duration of immunity of at least 9 months has been demonstrated. Bovi-Shield IBR may be administered to calves nursing pregnant cows provided their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD® FP® vaccine within the past 12 months.
To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP product with the second dose administered approximately 30 days prebreeding.
PRODUCT DESCRIPTION: Bovi-Shield IBR is a freeze-dried preparation of a modified live virus (MLV) strain of the IBR virus, plus a sterile diluent used to rehydrate the freeze-dried vaccine.
Directions For Use
General Directions: Vaccination of healthy, nonpregnant cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered SC in the neck region.
Primary Vaccination: Administer a single 2-mL dose to healthy cattle. To avoid possible maternal antibody interference with active immunization, calves vaccinated before the age of 6 months should be revaccinated after 6 months of age.
Revaccination: Annual revaccination with a single dose is recommended.
Good animal husbandry and herd health management practices should be employed.
Do not use in pregnant cows (abortions can result). Do not use in calves nursing pregnant cows unless their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD FP vaccine within the past 12 months.
Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
Burn containers and all unused contents.
Do not vaccinate within 21 days before slaughter.
Contains gentamicin as preservative.
As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished
or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 190
Zoetis Inc., Kalamazoo, MI 49007, USA
Presentation: 50-dose carton.
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the Bovi-Shield IBR information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2018 North American Compendiums. Updated: 2018-02-26